Imagen de Portada

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Fangyuan Jiang, Wenjing Yang, Yushu Cao, Xianghan Cao, Yu Zhang, Lingya Yao, Qian Cao
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
por: Fahim Ebrahimi, et al.
Publicado: (2024)

Review article: Evidence‐based dietary management of inflammatory bowel disease
por: Peter R. Gibson, et al.
Publicado: (2024)

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
por: Jianhui Zhao, et al.
Publicado: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
por: Tsz Hong Yiu, et al.
Publicado: (2024)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
por: Iris Barth, et al.
Publicado: (2024)

Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
por: Lingna Ye, et al.
Publicado: (2025)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
por: Maryam Kharal, et al.
Publicado: (2024)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
por: Carl Eriksson, et al.
Publicado: (2024)

Review article: Prevention of inflammatory bowel disease—The path forward
por: Sérgio Bronze, et al.
Publicado: (2024)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
por: Konstantinos Arvanitakis, et al.
Publicado: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
por: Nurulamin M. Noor, et al.
Publicado: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
por: Agnes Hiu Yan Ho, et al.
Publicado: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
por: Lana Bridi, et al.
Publicado: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
por: Rie Louise Møller Nordestgaard, et al.
Publicado: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
por: Amanda Ricciuto, et al.
Publicado: (2024)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
por: Thanaboon Chaemsupaphan, et al.
Publicado: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
por: Léa Sequier, et al.
Publicado: (2024)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
por: Arta Aliu, et al.
Publicado: (2024)

Letter: Light in the lumen—The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease
por: R. M. Mathias, et al.
Publicado: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
por: Christy Riggott, et al.
Publicado: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
por: D. Bogatic, et al.
Publicado: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
por: Ayesha Shah, et al.
Publicado: (2024)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
por: Aakash Desai, et al.
Publicado: (2024)

Inflammatory bowel disease in 2024 and beyond
por: Richard B. Gearry, et al.
Publicado: (2024)

Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
por: Kyuwon Kim, et al.
Publicado: (2024)

Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study
por: Mikkel Malham, et al.
Publicado: (2024)

Performance of bowel preparation quality scales in patients with Crohn's disease
por: Virginia Solitano, et al.
Publicado: (2024)

Duke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
por: Felicity R. Williams, et al.
Publicado: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
por: Liang Jiao, et al.
Publicado: (2026)

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
por: Cathy Lu, et al.
Publicado: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood
por: Paul Henderson
Publicado: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
por: Yewan Park, et al.
Publicado: (2024)

Letter: Irritable bowel syndrome and antibiotics
por: George F. Longstreth
Publicado: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
por: Mikkel Malham, et al.
Publicado: (2024)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
por: Runqi Wang, et al.
Publicado: (2026)

Editorial: Disordered eating and irritable bowel syndrome—Do maladaptive eating and weight control behaviours increase risk of a maladaptive gut?
por: Andrea Shin
Publicado: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
por: Nina Dominik, et al.
Publicado: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
por: Kyle Staller, et al.
Publicado: (2024)